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Obesity is associated with higher incidence of
cancer, but the predisposing mechanisms remain
poorly understood. The NAD+-dependent deacety-
lase SirT1 orchestrates metabolism, cellular survival,
andgrowth.However, there is nounifyingmechanism
to explain the metabolic and tumor-related effects
of SirT1. In this work, we demonstrate that genetic
ablation of the endogenous inhibitor of SirT1,
Deleted-in-Breast-Cancer-1 (Dbc1), unexpectedly
results in obesity and insulin resistance. Dbc1 defi-
ciency promoted SirT1-dependent gain of function
of stearoyl-coenzyme A desaturase 1 (Scd1), in-
creasingplasmaand tissue levels of unsaturated fatty
acids. The metabolic abnormalities in Dbc1–/– mice
were reversed by ablation of hepatic SirT1 or by inhi-
bition of Scd1 activity. Furthermore, loss of Dbc1
impaired activation of the master tumor suppressor
p53 and treatment with an Scd1 inhibitor extended
survival of tumor-prone TP53–/– mice by decreasing
tumor-related death. Together, our findings illustrate
a shared mechanism of obesity and tumor progres-
sion mediated by hepatic SirT1 and resulting in the
activation of a key lipid synthetic enzyme,with poten-
tial therapeutic implications.INTRODUCTION
The rising prevalence of obesity and overweight is expected to
result in 500,000 excess deaths from cancer by 2030 (Wang
et al., 2011). Although a well-documented association exists be-
tween obesity and cancer, especially among patients at the high-
est extremes of BMI distribution, it remains unclear whether the
association of obesity with cancer portends shared cellular andCebiochemical mechanisms, or simply reflects prevalent environ-
mental, behavioral, and genotoxic susceptibilities (Wang et al.,
2011). At the cellular level, multiple signaling pathways, such
as insulin/IGF, AKT, and mTORC, share metabolic and onco-
genic functions (Gallagher and LeRoith, 2013).
The NAD+-dependent, class III histone deacetylase (HDAC)
SirT1 is another important control node of metabolism and onco-
genesis (Chang and Guarente, 2014). SirT1 deacetylates pro-
teins with complex roles in metabolism, inflammation, aging,
cancer cell proliferation, and apoptosis. For example, it regulates
hepatic gluconeogenesis through FOXO1 (Frescas et al., 2005;
Qiang et al., 2010), white fat remodeling through peroxisome
proliferator-activated receptor gamma (PPARg) (Qiang et al.,
2012), mitochondrial biogenesis through peroxisome prolifera-
tor-activated receptor gamma coactivator 1-alpha (PGC1a)
(Rodgers et al., 2005), cholesterol metabolism through liver X re-
ceptor (LXR) (Li et al., 2007b), and other metabolic processes.
The overall metabolic effects of moderate SirT1 gain of function
are to lower energy efficiency and protect against obesity-
induced diabetes (Banks et al., 2008; Pfluger et al., 2008). With
regard to cancer biology, SirT1 deacetylates p53 to dampen its
tumor-suppressor function (Luo et al., 2001) and may also regu-
late retinoblastoma protein (Rb) (Wong and Weber, 2007), E2F1
(Wang et al., 2006), c-Myc (Mao et al., 2011), and Poly (ADP-
ribose) polymerase 1 (PARP-1) (Rajamohan et al., 2009). Never-
theless, to date, there is no unifying mechanism to explain the
metabolic and tumor-related effects of SirT1.
Deleted-in-breast-cancer-1 (Dbc1) is an endogenous inhibitor
of SirT1 (Kim et al., 2008; Zhao et al., 2008) that is expected to
regulate the latter’s ability to acetylate p53, thus promoting
cell-cycle arrest, apoptosis, and senescence (Li et al., 2012). In
support of this notion, it is found that regulation of SirT1 by
Dbc1 is altered in various types of cancers (Hiraike et al., 2011;
Kim et al., 2009; Sung et al., 2010), implicating a tumor suppres-
sor-like function of Dbc1. However, there is no direct evidence
that Dbc1 is a tumor suppressor. Similarly, there is evidence
that Dbc1 deletion prevents diet-induced hepatosteatosis in
mice, but the mechanism of this effect is not known (Escandell Reports 11, 1797–1808, June 23, 2015 ª2015 The Authors 1797
Figure 1. Dbc1–/– Mice Develop Insulin
Resistance and Obesity
(A) Areas under the curve (AUC) of glucose levels
following intraperitoneal glucose tolerance tests
(IPGTT) in chow-fed male mice of different ages
(n = 6 each).
(B) Plasma insulin levels of ad libitum-fed male
mice of the indicated ages (n = 9, 12).
(C) Body weight in both males and females (n = 12,
9, 10, 10 each).
(D) Body composition of 8-week-old, chow-fed
male mice (n = 11, 8).
(E and F) Total activity counts (E) and oxygen
consumption (F) in chow-fed 6-month-old male
mice (n = 6 each).
Data represent means ± SD, *p < 0.05, **p < 0.01.
See also Figures S1–S3.et al., 2010). Besides its function to inhibit SirT1, Dbc1 also reg-
ulates other chromatin remodeling enzymes, such as HDAC3
and SUV39H1, as well as transcription factors, including
androgen receptor, estrogen receptor a and b, RARa, Rev-
erba, MYC, andBRCA1, either as an activator or repressor (Joshi
et al., 2013). Interestingly, the interaction between Dbc1 and
SirT1 is regulated during diet-induced obesity (Escande et al.,
2010, 2015), raising the question of whether Dbc1 participates
in the etiology of the metabolic syndrome.
In this work, we set out to investigate the metabolic functions
of Dbc1 in association with its growth regulatory functions and
asked whether these functions are mediated by SirT1. In studies
of Dbc1-deficient mice, we found insulin resistance with in-
creased body fat content and impaired activation of tumor
suppressor p53. These changes were associated with increased
SirT1-dependent expression of Scd1, and altered tissue and
plasma levels of unsaturated fatty acids. When the increase
of Scd1 was reversed by pharmacological inhibition, meta-1798 Cell Reports 11, 1797–1808, June 23, 2015 ª2015 The Authorsbolic and tumor-progression phenotypes
were reversed, consistent with the possi-
bility that Scd1 mediates both metabolic
and oncogenic branches of the SirT1
pathway and providing a potential mech-
anism for the baffling increase of cancer
in metabolic diseases.
RESULTS
Dbc1–/– Mice Develop Insulin
Resistance and Increased Body Fat
Given the pivotal functions of SirT1 in the
pathophysiology of metabolic disorders,
we investigated whether its native inhibi-
tor Dbc1 also plays a role in metabolism.
To this end, we generatedDbc1 knockout
mice (Figures S1A–S1D). The knockouts
were born in Mendelian ratios and
showed normal features, growth rates,
and reproductive behavior. Since ablation
of Dbc1 increases SirT1 activity (Escandeet al., 2010, 2015), we expected thatDbc1–/–mice would bemore
insulin sensitive and protected against obesity-induced diabetes
(Banks et al., 2008; Pfluger et al., 2008). Surprisingly, Dbc1–/–
mice developed impaired tolerance to an intraperitoneal glucose
load as early as 16 weeks after birth and remained glucose intol-
erant throughout life (Figures 1A and S2A–S2E). Circulating insu-
lin levels also rose, consistent with systemic insulin resistance
(Figure 1B). These changes were not accompanied by changes
in body weight (Figure 1C), but rather by an increase in body fat
content beginning at puberty (Figures 1D and S2F). To explain
these changes,we studied energy balance using indirect calorim-
etry. Dbc1–/– mice had similar respiratory exchange ratios (RER)
as littermate controls (Figure S3A), but decreased locomotor
activity (Figure 1E) and O2 consumption (Figure 1F), as well as
energy expenditure (Figure S3B). SirT1 transgenics have similar
decreases (Banks et al., 2008), supporting a SirT1 gain of function
in Dbc1 knockouts. But, unlike SirT1 transgenics, Dbc1–/– had
similar food intake to control littermates (Figure S3C).
Figure 2. Metabolic Abnormalities of
Dbc1–/– Are Exacerbated by DIO
(A) Body weight of mice of both genders during
high-fat diet (HFD). *p < 0.05 between male wild-
type and knockout mice (n = 9, 9, 6, 9, respec-
tively).
(B) Body composition following HFD for 8 weeks
(n = 9 each).
(C) IPGTT following HFD for 13 weeks (n = 9 each).
(D) Plasma insulin levels in mice fed HFD for
24 weeks (n = 7 each).
(E) ITT following 9 weeks of HFD (n = 8, 10). The
metabolic characterization in (B)–(E) was con-
ducted in male mice.
(F) Basal endogenous glucose production (EGP)
during hyperinsulinemic-euglycemic clamps in
chow-fed male mice (n = 6, 4).
(G) Glucose production in primary hepatocytes
(n = 3 each). Data represent means ± SD,
*p < 0.05, **p < 0.01.Metabolic Abnormalities inDbc1–/–AreExacerbated by a
High-Fat Diet
Overexpression of SirT1 protects mice from obesity-induced in-
sulin resistance, but not obesity (Banks et al., 2008). In contrast,
when fed an obesogenic high-fat diet, Dbc1–/– mice displayed
increased body weight (Figure 2A) and body fat content (Fig-
ure 2B), further impairment of glucose tolerance (Figure 2C),
and higher insulin levels than wild-type controls (Figure 2D),
without changes to glucose levels (data not shown). These find-
ings, consistent with impaired insulin sensitivity, were borne
out by insulin tolerance tests (Figure 2E). Given the role of
SirT1 in regulating hepatic glucose production (Banks et al.,
2008), we tested whether glucose intolerance in Dbc1–/– was
due to hepatic insulin resistance. During hyperinsulinemic-eugly-
cemic clamps, Dbc1–/– mice displayed similar rates of glucose
infusion (GIR) and disposal (Rd) (data not shown) but increasedCell Reports 11, 1797–180basal hepatic glucose production (Fig-
ure 2F). In agreement with these findings,
we found that glucose production by pri-
mary hepatocytes isolated from Dbc1–/–
mice was also increased by 50%,
consistent with a cell-autonomous effect
(Figure 2G). In summary, Dbc1–/– mice
are prone to insulin resistance and diet-
induced obesity.
Increased Scd1 in Dbc1–/– Mice
Dbc1–/– mice have been reported to have
increased browning of white adipose
tissue (WAT), which should protect
them against the development of
obesity (Qiang et al., 2012). Thus, the
normal body weight in Dbc1–/– (Fig-
ure 1C) could represent a compensatory
mechanism from enhanced thermogene-
sis at ambient temperature. As expected,
knockouts gainedmore body weight than
controls at thermo neutrality (32C–33C)
(data not shown), further demonstrating a predisposition to
obesity in Dbc1–/–. We then hypothesized that their metabolic
alterations affect lipid homeostasis. Therefore, we surveyed
expression of genes required for lipid synthesis and turnover in
livers ofDbc1–/–mice. Strikingly, whereasmost regulators of lipid
transport and synthesis, including Srebf1, Fasn, Acc2, Dgat2,
Pparg, and Cd36, were expressed at or near wild-type levels,
expression of Scd1, the rate-limiting enzyme in fatty acid (FA)
desaturation, increased 3-fold above controls (Figure 3A). Eleva-
tion of Scd1 also occurred in livers of high-fat diet (HFD)-fed
Dbc1–/– mice. In this instance, it was accompanied by smaller
increases in other lipogenic genes (Figure 3B). Scd1 protein
levels mirrored themRNA findings (Figures 3C and 3D). To deter-
mine whether the increase in Scd1 was secondary to obesity
and/or hepatocyte cell autonomous, we assessed Scd1 activity
in primary hepatocytes isolated from youngDbc1–/–mice prior to8, June 23, 2015 ª2015 The Authors 1799
Figure 3. Increased Hepatic Scd1 in Dbc1–/– Mice
(A) qPCR analysis of hepatic gene expression from chow-fed male mice after 4 hr re-feeding following 16 hr fasting (n = 6 each).
(B) qPCR analysis of hepatic gene expression from male mice fed HFD for 9 weeks and fasted overnight prior to sacrifice (n = 6, 7).
(C) Western blot analysis of liver protein extracts from chow-fed mice in (A).
(D) Western blot analysis of liver protein extracts from HFD-fed mice in (B).
(E and F) Western blots analysis of protein extracts (E) and Scd1 activity (F) measured by CoA levels (n = 4 each) in primary hepatocytes isolated from 6-week-old
mice.
Data represent means ± SD, *p < 0.05, **p < 0.01. See also Figure S4 and Tables S1 and S2.the onset of obesity and insulin resistance. To this end, we
measured the ratio of the Scd1 product, stearoyl-CoA (C18:1),
to its substrate oleoyl-CoA (C18:0). We found that the C18:1/
C18:0 ratio increased 3-fold in Dbc1–/– versus wild-type hepato-1800 Cell Reports 11, 1797–1808, June 23, 2015 ª2015 The Authorscytes (Figure 3F), parallel to the levels of Scd1 (Figure 3E).
These data indicate that Scd1 activation is a cell-autonomous
effect of Dbc1 loss that precedes the onset of obesity in Dbc1
knockouts.
Paradoxical Protection from Atherosclerosis by
Deletion of Dbc1
Scd1 deficiency in mice has a paradoxical effect to increase
atherosclerosis while protecting them from obesity and insulin
resistance (Brown et al., 2008; MacDonald et al., 2009). We
then hypothesized that, if the metabolic phenotypes of Dbc1–/–
aremediated by Scd1,Dbc1 knockouts should also be protected
from atherosclerosis. In Dbc1–/–:Ldlr–/– double knockouts fed a
Western-type diet (WTD), we confirmed the increase of Scd1
(Figures S4A and S4B) as well as a constellation of atherogenic
findings, including increased body weight, hepatosteatosis, dys-
lipidemia, and insulin resistance (Table S1). However, athero-
sclerotic lesion size was decreased in Dbc1–/–:Ldlr–/– mice,
consistent with a protective function of Scd1 against plaque for-
mation (Erbay et al., 2009), and in line with the reduced athero-
sclerosis in Dbc1-deficient ApoE–/– mice (Escande et al., 2015).
These data buttress the conclusion that Scd1 activation is mech-
anistically responsible for the phenotype of Dbc1–/– mice.
Indeed, the metabolic sub-phenotypes of Dbc1–/– mice are
opposite to those found in Scd1-deficient mice (Table S2).
Dbc1 Deletion Further Impairs Metabolic Control in
ob/ob Mice
Scd1 ablation reduces body weight in leptin-deficient ob/ob
mice (Cohen et al., 2002). Thus, we asked whether deletion
of Dbc1 affects obesity in ob/ob mice. As expected, we saw
increased body weight, fat content, decreased lean mass, and
impaired glucose tolerance in Dbc1–/–:ob/ob mice (Figures
S4C–S4E). The additive effects of the Dbc1 and ob mutations
indirectly rule out impaired leptin signaling as a primary cause
of obesity and insulin resistance in Dbc1–/– mice.
Inhibition of Scd1 Restores Metabolic Homeostasis in
Dbc1–/– Mice
To test whether the metabolic abnormalities of Dbc1–/– mice
were mediated by Scd1, we treated HFD-fed mice with the
Scd1 inhibitor, A939572 (Flowers et al., 2011; Paton and Ntambi,
2010). Treatment with low doses of inhibitor affected weight gain
in control mice as expected but, more importantly, normalized
body weight gain (Figure 4A) and abnormal body composition
in the knockouts (Figures 4B and 4C). Consistent with our find-
ings in primary hepatocytes (Figure 3F), monounsaturated FA
content (MUFA, C18:1) increased in livers of Dbc1–/– mice and
were normalized by treatment with the inhibitor (Figure 4D).
There was no effect on hepatic lipid content (Figures S5A–
S5C). Furthermore, glucose intolerance in Dbc1–/– mice was
also improved by low-dose Scd1 inhibitor treatment (5 versus
10–100 mg/kg/day) (Figure 4E). These data support the conclu-
sion that the metabolic effects of Dbc1 ablation require Scd1
gain of function.
Metabolic Abnormalities in Dbc1–/– Mice Are SirT1
Dependent
Next, we asked whether the metabolic functions of Dbc1 are
mediated through SirT1. To this end, and given the lethality asso-
ciated with complete SirT1 deletion, we generated liver-specific
Sirt1 knockouts (L-SirT1) (Figure 5A). Unlike control mice
(Sirt1fl/fl:Dbc1/) (Figures S6A and S6B), L-SirT1:Dbc1–/– miceCeshowed normal bodyweight (Figure S6C), fat content (Figure 5B),
and glucose tolerance (Figure 5C). In fact, obesity and glucose
intolerance in young Dbc1–/– mice were completely reversed by
hepatic SirT1 deletion (Figures S6D and S6E). When fed HFD,
L-SirT1:Dbc1–/–mice gained lessweight than controls (Figure 5E)
and showedno increase in body fat (Figure 5F).More importantly,
Sirt1 ablation prevented the increase of Scd1 in livers of
L-SirT1:Dbc1–/– mice (Figure 5D). Taken together, the metabolic
abnormalities in Dbc1–/– mice were offset by blocking SirT1-
dependent upregulation of Scd1 in the liver.
Scd1 Is Regulated by Dbc1 and SirT1
To understand the biochemical basis of the interaction among
SirT1, Dbc1, and Scd1, we examined whether SirT1 and Dbc1
regulate activity of a minimal Scd1 promoter encompassing
1,537/+155 (Chu et al., 2006). Wild-type SirT1, but not its cata-
lytically inactive mutant (H363Y), stimulated Scd1 promoter ac-
tivity, while Dbc1 repressed it (Figure 6A). Chemical inhibition
of SirT1 repressed Scd1 promoter activity, without affecting
the related Fasn promoter (Figure 6B). Deletion mapping local-
ized the Dbc1/SirT1 interaction site between bp 981 and
589 (Figure 6C). Chromatin immunoprecipitation assays further
confirmed binding of Dbc1 to Scd1 promoter between bp 807
to 428 (Figure 6D). Moreover, transient knockdown of DBC1
increased SCD1 levels in human non-small cell lung cancer cells
(Figure 6E), indicating that Dbc1 is a conserved negative regu-
lator of Scd1 in normal and carcinoma cells. Collectively, these
data suggest that the deacetylase activity of SirT1 increases
Scd1 expression, and that Dbc1 inhibits Scd1 by blocking SirT1.
Impaired p53 Activation in Dbc1–/– Mice
Next, we investigated the tumor-promoting properties of Dbc1.
As predicted,Dbc1 ablation reduced p53 acetylation and activa-
tion of its target genes p21 and puma in mouse embryonic fibro-
blasts (MEFs), following doxorubicin-induced DNA damage (Fig-
ures S7A and S7B). We then asked whether Dbc1 is a de facto
tumor suppressor. Ionizing radiation induces p53, resulting in
apoptosis, as indicated by the presence of cleaved caspase-3
in thymus and spleen of irradiated wild-type animals (Figures
7A and 7B). Consistent with the findings in MEFs, Dbc1–/– mice
showed a blunted p53 response and reduced caspase-3 cleav-
age (Figure 7B). Based on the reduced p53 activation by DNA
damage, we expected increased tumorigenesis in Dbc1–/–
mice. But to our surprise, spontaneous tumors arose in aging
Dbc1–/– mice at the same rate as in wild-type controls (data
not shown). Thus, Dbc1 deletion is not oncogenic per se but is
expected to accelerate cancer progression owing to impaired
p53 activation.
Scd1 Inhibition Prevents Cancer Progression in TP53–/–
Mice
Similar metabolic abnormalities to those observed in Dbc1
knockouts are associated with increased risk of cancer (Gal-
lagher and LeRoith, 2013). Mice deficient in p53 (TP53–/–)
develop spontaneous tumors and die by 6 months of age (Jacks
et al., 1994). Interestingly, lack of p53 in primary hepatocytes
increased levels of Scd1 andMUFAs (Figures 7C and 7D). There-
fore, we investigated whether the metabolic alterations inll Reports 11, 1797–1808, June 23, 2015 ª2015 The Authors 1801
Figure 4. Inhibition of Scd1 Reverses Metabolic Abnormalities in Dbc1–/– Mice
(A) 12- to 16-week-old male mice were injected daily with Scd1 inhibitor after starting HFD feeding. Body weight change after 20 days of treatment. p < 0.0001 by
two-way ANOVA.
(B) Lean mass after 18 days of treatment. p = 0.001 by two-way ANOVA.
(C) Fat mass after 18 days of treatment. p < 0.0001 by two-way ANOVA.
(D) Hepatic Scd1 activity plotted as MUFA to saturated FA ratios at 4 weeks of Scd1 inhibitor treatment. p = 0.017 for C16:1/C16 and p = 0.004 for C18:1/C18 by
two-way ANOVA.
(E and F) IPGTT (E) and areas under curve (AUC) (F) after 3 weeks of inhibitor treatment. p = 0.001 for AUC by two-way ANOVA. Statistically significant differences
between two groups were calculated by post hoc Tukey honest significant difference (HSD) test. Levels not connected by the same letter (a, b, c) are significantly
different.
Data represent means ± SD, n = 6 each group. See also Figure S5.Dbc1–/– mice affected cancer susceptibility in an Scd1-depen-
dent manner. Although SCD1 inhibitor has been shown to induce
apoptosis in cultured cancer cells (Hess et al., 2010), and
decrease tumor growth in a human gastric xenograft model at
high doses (100 mg/kg/BID) (Roongta et al., 2011), its anti-tumor
function has never been tested in vivo. As a critical test of our
hypothesis, we fed TP53–/– mice HFD and treated them with
the Scd1 inhibitor at physiological dose (5 mg/kg/day). Inhibi-
tor-treated mice mimicked aspects of Scd1-deficient mice,
including fur loss, eyelid closure, and body-weight reduction
(Miyazaki et al., 2001; Ntambi et al., 2002). Importantly, we
observed a substantial reduction of tumor-related death and a
28% increase of median lifespan among inhibitor-treated mice,
compared to untreated controls (Figure 7E).1802 Cell Reports 11, 1797–1808, June 23, 2015 ª2015 The AuthorsDISCUSSION
Here, we report that SirT1-dependent elevation of Scd1 ac-
counts for obesity and insulin resistance in Dbc1–/– mice under
multiple genetic and dietary manipulations. Loss of Dbc1
enhanced SirT1 activity, consistent with previous studies in
Dbc1 knockout mice (Escande et al., 2010, 2015).
It is surprising that the gain of function of SirT1 associated with
Dbc1 ablation caused obesity and insulin resistance, unlike the
gain of function caused by SirT1 overexpression in transgenic
mice (Banks et al., 2008; Pfluger et al., 2008). In the latter models,
SirT1 is overexpressed at levels about 2-fold higher than endog-
enous and is still under control by Dbc1, whereas, in Dbc1–/–
mice, SirT1 is constitutively active. This provides a potential
Figure 5. Metabolic Abnormalities of Dbc1–/– Are Mediated by Hepatic SirT1
(A) Validation of liver-specific SirT1 knockout (L-SirT1) by western blotting of liver protein extracts.
(B and C) Body composition (B) and IPGTT (C) in 19-week-old L-SirT1 mice and double knockouts on chow diet (n = 6 each).
(D) qPCR analysis of hepatic gene expression in chow-fed, overnight-fasted 21-week-old mice (n = 6 each).
(E) Body weight of L-SirT1 mice on HFD for 5 weeks or 8 weeks.
(F) Body composition after 8-week HFD (n = 7 and 6). All experiments were performed in male mice.
Data represent means ± SD, *p < 0.05. See also Figure S6.explanation for the fact that Scd1 is increased inDbc1–/–, but not
in SirT1 transgenic mice (Qiang et al., 2011). In support of this
notion, increased Scd1 expression was observed in b cells
with 12- to 18-fold overexpression of Sirt1 (Moynihan et al.,
2005; Ramsey et al., 2008). The increase of Scd1 by unchecked
SirT1 activation is likely responsible for the unexpected obesity
and insulin resistance of Dbc1–/– mice.
Several transcriptional factors, including SREBP-1c, LXRa,
and PPARs, activate Scd1 (Chu et al., 2006; Paton and
Ntambi, 2009). However, to our knowledge, no Scd1 repres-
sors are known thus far. Our mapping data have identified a
region in the promoter through which Dbc1 represses Scd1.
The consensus binding sites for C/EBP, NF-Y/NF-1, SRE,
Sp1 in the mouse Scd1 promoter are conserved in the human
SCD1 promoter (Bene´ et al., 2001). Notably, we also saw
regulation of SCD1 by DBC1 knockdown in human cancer
cells (Figure 6E; data not shown). We do not know whether
the repression is direct or indirect, but it is unlikely to be medi-
ated by Srebp-1c, as it is not associated with increases of
other Srebp-1c targets, such as Fasn. Moreover, expression
patterns of Scd1 and Srebp-1c are distinct in Dbc1–/– mice.
Finally, Scd1 repression by Dbc1 requires SirT1 deacetylaseCeactivity, suggesting that it involves deacetylation of transcrip-
tional regulators.
Ablation ofDbc1 is not oncogenic per se but likely favors tumor
progression by impairing p53 activation through unchecked SirT1
activity. The function of SirT1 in cancer is context dependent
(Deng, 2009). SirT1 haploinsufficiency promotes spontaneous
tumor development in TP53+/– mice, while overexpression of
SirT1 in lymphocyte progenitors reduces the incidence of thymic
lymphomas in TP53+/– mice post g-irradiation, consistent with a
tumor-suppressor function of SirT1. On the other hand, SirT1 is
elevated in human leukemia, as well as prostate, colon, skin,
andsomehepatocellular cancers.Moreover,SirT1 levelscorrelate
with malignancy of hepatocellular carcinoma. As SirT1 also
impairs p53 acetylation and regulation of cell cycle, apoptosis,
and senescence (Li et al., 2012), a possible explanation of this
apparent discrepancy is that SirT1 inhibits tumor initiation in
normal cells but facilitates progression in established tumors
(ChangandGuarente, 2014;Chenetal., 2012). This view isconsis-
tent with the present observation that the tumor-promoting func-
tion of Dbc1 ablation is associated with SirT1 activation, as well
aswith evidence of impaired regulation of SirT1 byDbc1 in certain
cancers (Hiraike et al., 2011; Kim et al., 2009; Sung et al., 2010).ll Reports 11, 1797–1808, June 23, 2015 ª2015 The Authors 1803
Figure 6. Dbc1 and SirT1 Regulate Scd1
(A) Scd1 luciferase reporter assay in 293 cells
transfected with control plasmid (RFP), plasmids
encoding SirT1, deacetylase-defective SirT1
mutant H363Y (HY) or Dbc1 (n = 4 each).
(B) Full-length Scd1 luciferase reporter assay in 293
cells treated with the SirT1 inhibitor 10 mM nico-
tinamide (Nam) or vehicle (Veh) for overnight. Fasn
reporter was used as control (n = 4 each).
(C) Truncated Scd1 promoter luciferase assay in
293 cells transfected with control plasmid (RFP) or
plasmids encoding SirT1 or Dbc1. Fasn reporter
was used as a control (n = 4 each).
(D) Chromatin immunoprecipitation of Dbc1 on
Scd1 promoter in MEFs.
(E) Western blots following transient DBC1 knock-
down in human lung cancer H1299 cells.
Data represent means ± SD, *p < 0.05, **p < 0.01.
Luciferase reporter assays were repeated at least
three times.Our findings suggest a mechanism whereby tumor progres-
sion genes can leverage a metabolic control step to promote
cancer growth. Scd1 is the rate-limiting enzyme in generating
mono-unsaturated FAs (MUFA). In addition to its critical role in
lipid storage and obesity, unsaturated FA synthesis is required
for membrane biogenesis, fluidity, and permeability, and hence
by rapidly growing tumor cells. MUFAs are also involved in signal
transduction to support cancer cell growth (Atilla-Gokcumen
et al., 2014; Igal, 2011). Elevated Scd1 levels have been found
in various human cancers with increased lipid desaturation (Fritz
et al., 2010; Ide et al., 2013; Roongta et al., 2011; von Roemeling
et al., 2013). These types of cancer are also commonly associ-
ated with obesity (Calle et al., 2003; Wang et al., 2011). Treat-
ment with Scd1 inhibitor decreases proliferation and induces
apoptosis in cancer cells (Hess et al., 2010; Roongta et al.,
2011). Of particular interest is that theses anti-proliferative and
pro-apoptotic effects of Scd1 inhibition are selective to tumor
cells, but not to normal cells (von Roemeling et al., 2013). There-
fore, the coordinated regulation of Scd1 by Dbc1 and SirT1 pro-
vides a heretofore-unknownmechanism for the predisposition to
cancer associated with obesity.
The metabolic abnormalities in our Dbc1–/– mice are largely
consistent with those in knockouts generated by genetrap
methodology (Escande et al., 2010, 2015; Nin et al., 2014). In
the latter model, female mice developed a ‘‘fit obese’’ pheno-
type, i.e., obesity with insulin sensitivity, and reduced adipocyte
lipolysis (Escande et al., 2015). Neither in two previous reports
(Escande et al., 2015; Nin et al., 2014), nor in our study are males1804 Cell Reports 11, 1797–1808, June 23, 2015 ª2015 The Authorsprotected from diet-induced insulin resis-
tance, raising the possibility of sex-dimor-
phic actions of Dbc1. We did not observe
protection from diet-induced steatosis
on chow/HFD feeding (data not shown)
or through Scd1 inhibition (Figure S5),
possibly due to different knockout strate-
gies or experimental conditions. However,
both Dbc1 knockout models showed
protection from atherosclerosis (Escande
et al., 2015), in line with the anti-atherogenic functions of Scd1
(Erbay et al., 2009). The implication of the atherosclerosis studies
is that targeting Dbc1/Scd1/MUFA may lessen the burden of
atherosclerosis in obesity and type 2 diabetes.
In sum, we have uncovered a shared obesogenic and tumor-
promoting mechanism resulting from gain of function of the
fatty acid desaturase, Scd1, through derepression of SirT1.
Our study, along with our previous report of pro-atherogenic
effects of SirT1 (Qiang et al., 2011), adds to a body of work
that invites caution in exploring the therapeutic applications of
SirT1 activators (Alcain and Villalba, 2009; Chang and Guarente,
2014; Chen et al., 2008; Li et al., 2007b; Ng and Tang, 2013). In
addition, our study contributes to mapping pathways of disease
progression connecting obesity, insulin resistance, and cancer
may thus pave the way to treating metabolic syndrome-related
cancers.
EXPERIMENTAL PROCEDURES
Generation of Dbc1 Knockout Mice
To construct Dbc1 gene targeting vector, a fragment of Dbc1 genomic DNA,
containing 5.5 kb DNA 50 of exon 1 and 1.8 kb 30 of exon 1, was cloned by re-
combineering. Next, a promoter-less EGFP was inserted in exon 1 in frame
next to the translation start codon (ATG) along with a neomycin resistance
gene cassette allowing selection by G418. The targeted allele permits expres-
sion of EGFP controlled by endogenous Dbc1 promoter (Figure S1A). The
clones containing EGFP-neo cassette insertion through homologous recombi-
nation were screened by Southern blotting using EcoRV digested embryonic
stem cell (ESC) genomic DNA and an external 30 probe, amplified using for-
ward primer 50-GTT GAT GAT ACA TTT TGA TCT CA-30 and reverse primer
Figure 7. Dbc1 Ablation Facilitates Tumor Progression through Increased Scd1
(A) Prostate immunohistochemistry (IHC) in Dbc1–/– mice subjected to the indicated doses of g-radiation.
(B) Western blots of spleen protein extracts from mice in (A).
(C) Western blot analysis of proteins in primary hepatocytes isolated from TP53–/– mice. Cells were treated overnight with 1.67 mM insulin.
(D) MUFA content in primary hepatocytes isolated from TP53–/– mice. Data represent means ± SD, **p < 0.01 (n = 4).
(E) Kaplan-Meier survival plots of TP53–/–male and femalemice following treatment with Scd1 inhibitor. Statistical significancewas estimated by log rank (Mantel-
Cox) test (n = 23 each).
See also Figure S7.50-AAG GTA GGA GCA GCA GAA ACC TG-30 (Figure S1B). Targeted ESC
clones were injected into C57BL6/j blastocysts to derive chimeras, fromwhich
the targeted allele was transmitted successfully.CeAnimal Studies
Dbc1–/– mice were on 129/J 3 C57BL/6J background and TP53–/– mice on
C57BL/6J background. Lepob/+ mice were from Jackson Laboratory. Ldlr–/–,ll Reports 11, 1797–1808, June 23, 2015 ª2015 The Authors 1805
a1-antitrypsin-cre transgenic (AT-Cre), and Sirt1fllox/flox mice (Li et al., 2007a)
have been described. Mice were housed at ambient temperature in a 12-hr
light/dark cycle and fed ad libitum normal chow (PicoLab rodent diet 20) (Lab-
Diet 5053), 60 kcal% high-fat diet (Research Diet, D12492), or WTD (TD88137,
Harlan Teklad). Metabolic characterization was performed as described
(Banks et al., 2008; Qiang et al., 2011, 2012). All experiments were performed
in male mice unless indicated. The Columbia University Animal Care and
Utilization Committee approved all procedures.
Scd1 Inhibitor Treatment
For acute Scd1 inhibitor treatment, we injected A939572 (Biofine) intraper-
itoneally (i.p.) daily at a dose of 5 mg/kg starting on the same day as HFD.
For chronic treatment in TP53–/– mice, the inhibitor was mixed with 60 kcal
% HFD at a dose of 100 mg/kg. Scd1 activities were determined by
measuring saturated and unsaturated CoA concentrations at the Bio-
markers Core Lab of the Irving Institute for Clinical and Translational at
Columbia University.
Cell Culture and Scd1 Luciferase Reporter Assay
We transiently transfected HEK293T cells (12-well) with 0.2 mg Luciferase re-
porter plasmids and 0.02 mg Renilla control plasmid, together with 0.2 mg indi-
cated SirT1 or Dbc1 plasmids using TransIT-LT1 reagent (Mirus Bio). We then
performed Dual-luciferase reporter assay by following the manufacturer’s in-
structions (Promega). Mouse Scd1 promoter luciferase reporters (1,537/
+155, 981/+155, 589/+89) are generously provided by Dr. James Ntambi
(Chu et al., 2006). The Fasn luciferase reporter was used as a control. Glucose
production in primary hepatocytes was performed as described (Pajvani et al.,
2013).
Protein Analysis
Proteins were extracted into protein lysis buffer (50 mM Tris [pH 7.4], 150 mM
NaCl, 10% glycerol, 2% NP-40, 1 mM EDTA [pH 8.0], 0.1% SDS, 0.5% Na-
DOC) supplemented with protease and phosphatase inhibitors. Antibodies
used were: Dbc1 (Bethyl Laboratories, note: nonspecific signal at 135 kDa
for freshly made working solution), p53 (CM5, Leica Microsystems), Puma
(Sigma-Aldrich), SirT1 (Millipore), and p21 and tubulin (Santa Cruz Biotech-
nology). Scd1, Fas, cleaved caspase-3, Ac-p53, p-Akt (S473), p-Akt (T308),
Akt, and actin antibodies were purchased from Cell Signaling Technology.
Horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Health-
care) were used for detecting enhanced chemiluminescence (ECL) western
blot signals.
Gene Expression Analysis
Total RNA was isolated with RNeasy Lipid Tissue kit (QIAGEN), and 1 mg RNA
was subjected to cDNA synthesis by using High-capacity cDNA Reverse
Transcription kit (Applied Biosystems). We performed qPCR with goTaq
qPCR Master Mix (Promega) on CFX96 Real-Time PCR system (Bio-Rad).
The relative gene expression levels were calculated by DDCt method with
cyclophilin A as the reference gene. qPCR primers were as listed (Qiang
et al., 2011, 2012).
Chromatin Immunoprecipitation Assay
We performed chromatin immunoprecipitation (ChIP) analysis of Dbc1 on
Scd1 promoter by using ChIP assay kit following manufacturer’s instructions
(EMD Millipore). Anti-Dbc1 (Bethyl Laboratories) was used.
Histology
We used paraffin-embedded sections for Dbc1, p53, and caspase-3 immuno-
histochemistry (all at 1:100 dilution) and frozen liver sections for oil red O
staining.
Statistical Analysis
We performed unpaired two-tailed Student’s t tests for single measure-
ments and two-way ANOVA with Tukey post hoc analysis where appro-
priate by using JMP software (SAS) to evaluate statistical significance.
p < 0.05 was considered as a significant change. All values are presented
as means ± SD.1806 Cell Reports 11, 1797–1808, June 23, 2015 ª2015 The AuthorsSUPPLEMENTAL INFORMATION
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